Transaction #33255 · Form 4 · 0001829126-26-011084

TRex Bio, Inc. · Conversion · Common Stock

TRex Bio, Inc. · Transacted October 13, 2026 · Filed October 13, 2026

Original SEC filing ↗

What does this filing report?

An SEC Form 4 filing for TRex Bio, Inc. records a conversion involving Common Stock on October 13, 2026. The reported quantity was 53,892. The filing date is October 13, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.

The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.

Transaction details

Company CIK
0002139097
Security type
Non-derivative
Acquisition type
Conversion · Code C
Quantity acquired
53,892
Reported price
0
Reference value
0
Currency
Currency not specified
Ownership
Indirect
Holdings after transaction
61,248
Ownership description
By SV Life Sciences Fund VI Strategic Partners, L.P.
SEC acceptance time
Oct 13, 2026, 4:30 PM EDT
10b5-1 indication
Not indicated

Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.

Reporting owners

These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.

Company listings

TRXB · Nasdaq · linked security

The linked listing is identified separately from other current company listings.

Filing footnotes & remarks

F1
The shares are held directly by SV Life Sciences Fund VI, L.P. ("SV Fund VI"). SV Life Sciences Fund VI (GP), L.P. (the "GP LP") is the general partner of SV Fund VI, and SVLSF VI, LLC ("SVLSF") is the general partner of GP LP. Investment and voting decisions of SV Fund VI are made by the investment committee of SVLSF. Each of GP LP and SVLSF disclaims beneficial ownership except to the extent of its pecuniary interest, and this report is not an admission of beneficial ownership for any other purpose.
F2
The shares are held directly by SV Life Sciences Fund VI Strategic Partners, L.P. ("SV Strategic Partners VI"). GP LP is the general partner of SV Strategic Partners VI, and SVLSF is the general partner of GP LP. Investment and voting decisions of SV Strategic Partners VI are made by the investment committee of SVLSF. Each of GP LP and SVLSF disclaims beneficial ownership except to the extent of its pecuniary interest, and this report is not an admission of beneficial ownership for any other purpose.
F3
The shares are held directly by SV Trex Coinvestment, L.P. ("SV Coinvestment"). GP LP is the general partner of SV Coinvestment, and SVLSF is the general partner of GP LP. Investment and voting decisions of SV Coinvestment are made by the investment committee of SVLSF. Each of GP LP and SVLSF disclaims beneficial ownership and this report is not an admission of beneficial ownership for any other purpose.
F4
On October 13, 2026, 3.8649 shares of preferred stock automatically converted into one share of common stock upon the closing of the issuer's initial public offering, for no additional consideration. The preferred stock has no expiration date.
F5
Represents shares purchased by SV Fund VI in the issuer's initial public offering.
F6
Represents shares purchased by SV Strategic Partners VI in the issuer's initial public offering.

Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.

This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.